-
公开(公告)号：EP3804758A1
公开(公告)日：2021-04-14
申请号：EP19812634.4
申请日：2019-05-30
发明人： NISHIKAWA, Hiroyoshi , TOGASHI, Yosuke , OHYAMA, Yukiya , YOSHIDA, Takao , TAKEDA, Kazuhiko , KODA, Kenichi , HONDA, Atsushi , OYAGI, Atsushi , KAKINUMA, Toru , MURATA, Masayuki
摘要： The present invention addresses the problem of providing: a method for identifying a malignant tumor patient in whom an immune checkpoint inhibitor can be expected to be more effective; and an agent for suppressing the advance, suppressing the recurrence, and/or treating a malignant tumor characterized by prescription based on the method. The present invention provides: the determination of a malignant tumor patient in whom an immune checkpoint inhibitor can be expected to be more effective, said determination being made by analyzing evaluation items comprising a combination of PD-1 expression intensity and proportion of PD-1 expressing cells, etc., in Treg cells and CD8 + T cells in tumor tissue or blood; and an agent for suppressing the advance, suppressing the recurrence, and/or treating a malignant tumor characterized by prescription based on the determination.
-
公开(公告)号：EP1591527B1
公开(公告)日：2015-08-26
申请号：EP04704324.5
申请日：2004-01-22
发明人： HONJO, Tasuku , SHIBAYAMA, Shiro , TAKEDA, Kazuhiko , MATSUO, Masayoshi , YOSHIDA, Takao , MIYAMOTO, Masakazu
IPC分类号： C12N15/13 , C07K16/46 , C12P21/08 , C12N5/10 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/56 , C07K2317/73
-
公开(公告)号：EP3482760A1
公开(公告)日：2019-05-15
申请号：EP17824314.3
申请日：2017-07-06
IPC分类号： A61K31/277 , A61K45/00 , A61P35/00 , A61P43/00
摘要： The present invention addresses the problem of discovering an effective cancer therapy method and providing a medicine. Provided is a medicine comprising a combination of a compound represented by general formula (I), a salt, solvate or N-oxide of the compound or a prodrug of the compound or the salt, solvate or N-oxide and an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody). The combination according to the present invention exhibits a high anti-tumor effect and is therefore useful for the treatment of cancer.
-
4.发明公开USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS 审中-公开有效性标记技术用于优化对肿瘤的抗人PD-1ANKÖRPERS的治疗功效
公开(公告)号：EP2307050A1
公开(公告)日：2011-04-13
申请号：EP09773195.4
申请日：2009-07-03
发明人： SHIBAYAMA, Shiro , YOSHIDA, Takao , HAYASHI, Tamon , HAYASHI, Akio , MURAI, Jun
IPC分类号： A61K39/395 , A61P35/00 , A61P35/02 , G01N33/53
CPC分类号： C07K16/2818 , A61K2039/505 , G01N2800/52
摘要： A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
-
-
-
搜索结果
4 条记录 (耗时 0.016 秒)
